Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Total Current Liabilities (2016 - 2026)

OptimizeRx's Total Current Liabilities history spans 16 years, with the latest figure at $21.3 million for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 13.99% to $21.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $21.3 million, a 13.99% increase, with the full-year FY2025 number at $21.3 million, up 13.99% from a year prior.
  • Total Current Liabilities hit $21.3 million in Q4 2025 for OptimizeRx, up from $18.5 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for OPRX hit a ceiling of $21.3 million in Q4 2025 and a floor of $5.4 million in Q1 2021.
  • Historically, Total Current Liabilities has averaged $12.0 million across 5 years, with a median of $8.9 million in 2021.
  • Biggest five-year swings in Total Current Liabilities: tumbled 45.22% in 2021 and later surged 171.45% in 2024.
  • Tracing OPRX's Total Current Liabilities over 5 years: stood at $9.4 million in 2021, then dropped by 10.38% to $8.4 million in 2022, then surged by 112.99% to $17.9 million in 2023, then rose by 4.32% to $18.7 million in 2024, then grew by 13.99% to $21.3 million in 2025.
  • Business Quant data shows Total Current Liabilities for OPRX at $21.3 million in Q4 2025, $18.5 million in Q3 2025, and $21.1 million in Q2 2025.